Ventricular Tachycardia (V-tach or VT) Pipeline Analysis Report 2026

Ventricular Tachycardia (V-tach or VT) Pipeline Analysis highlights a life-threatening cardiac arrhythmia characterized by a rapid heart rhythm originating in the ventricles. According to Christopher Foth et al., 2023, ventricular tachycardia and fibrillation contribute to nearly 300,000 sudden cardiac deaths annually in the United States. The ventricular tachycardia treatment pipeline, VT drug development trends, and antiarrhythmic therapies research are gaining momentum, with innovations in catheter ablation, gene therapies, and targeted drugs. According to the ventricular tachycardia (V-tach or VT) pipeline analysis, increasing R&D and demand for effective rhythm control solutions are expected to drive significant growth in the coming years.

Report Coverage

The Ventricular Tachycardia (V-tach or VT) Pipeline Analysis Report gives comprehensive insights into ventricular tachycardia (V-tach or VT) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ventricular tachycardia (V-tach or VT). The ventricular tachycardia (V-tach or VT) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The ventricular tachycardia (V-tach or VT) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with ventricular tachycardia (V-tach or VT) treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to ventricular tachycardia (V-tach or VT).

Ventricular Tachycardia (V-tach or VT) Pipeline Outlook

Ventricular tachycardia (V-tach or VT) is a serious cardiac arrhythmia characterized by a rapid heart rhythm originating in the ventricles. It occurs due to abnormal electrical impulses, often linked to cardiac arrhythmia mechanisms, ventricular dysfunction triggers, or underlying structural heart diseases, leading to reduced cardiac output and compromised circulation.

Ventricular tachycardia (V-tach or VT) treatment includes antiarrhythmic drugs, catheter ablation, and implantable cardioverter-defibrillators. Emerging approaches focus on targeted cardiac therapy, advanced rhythm control strategies, and improved emergency interventions to stabilize heart rhythm. In December 2025, the United States Food and Drug Administration approved etripamil nasal spray for paroxysmal supraventricular tachycardia, highlighting progress relevant to the pipeline. This advancement supports antiarrhythmic drug innovation and rapid, patient-administered therapies in acute arrhythmia management.

Ventricular Tachycardia (V-tach or VT) Epidemiology

The pipelinereflects growing focus on high-risk populations and unmet needs. As per Christopher Foth et al., 2023, ventricular tachyarrhythmias contribute to nearly 300,000 deaths annually in the United States. The ventricular tachycardia incidence rate is higher among patients with coronary artery disease, affecting nearly 15% of cases. Additionally, acute myocardial infarction-related ventricular arrhythmias occur in 5-10% of patients. According to recent data, the idiopathic ventricular tachycardia incidence is approximately 15 per 100,000 individuals, with increasing diagnosis due to improved awareness and screening practices.

Ventricular Tachycardia (V-tach or VT) - Pipeline Therapeutic Assessment

This section of the report covers the analysis of ventricular tachycardia (V-tach or VT) drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase 1)
• Preclinical and Discovery Stage Products

By Drug Class

The ventricular tachycardia (V-tach or VT) pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Gene Therapies
• Neuropeptides
• Triglycerides

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Ventricular Tachycardia (V-tach or VT) Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 37%, covers a major share of the total ventricular tachycardia (V-tach or VT) clinical trials, driven by active clinical validation and strong mid-stage momentum, significantly shaping future treatment options. Phase III accounts for 26%, reflecting late-stage confidence and near-market impact. Phase I contributes 16%, indicating early innovation. Phase IV also represents 16%, supporting post-marketing value. Early phase I at 5% highlights emerging exploration research strengthening the pipeline.

Ventricular Tachycardia (V-tach or VT) Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the ventricular tachycardia (V-tach or VT) pipeline analysis include small molecules, gene therapies, neuropeptides, and triglycerides. The ventricular tachycardia (V-tach or VT) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ventricular tachycardia (V-tach or VT). Ion channel-modulating therapies are emerging as a targeted approach in the pipeline. For instance, CRD-4730, a novel investigation agent, is under clinical evaluation for catecholaminergic polymorphic ventricular tachycardia. Moreover, precision-based antiarrhythmic drugs are being explored to regulate abnormal cardiac electrical activity, thereby improving rhythm stability and reducing the risk of sudden cardiac events.

Ventricular Tachycardia (V-tach or VT) Clinical Trials - Key Players

The report for the ventricular tachycardia (V-tach or VT) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ventricular tachycardia (V-tach or VT) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in ventricular tachycardia (V-tach or VT) clinical trials:

• Cardurion Pharmaceuticals, Inc.
• Solid Biosciences Inc.
• Milestone Pharmaceuticals Inc.
• Link Medical Research AS
• Viedoc Technologies AB
• Vitas AS
• Biosense Webster, Inc.
• Abbott Medical Devices
• Biotronik SE & Co. KG
• Agiana Pharmaceuticals

Ventricular Tachycardia (V-tach or VT) - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for ventricular tachycardia (V-tach or VT). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of ventricular tachycardia (V-tach or VT) drug candidates.

Drug: Etripamil NS 70 mg

Etripamil Nasal Spray is being developed by Milestone Pharmaceuticals Inc. as a fast-acting, self-administered calcium channel blocker delivered intranasally for acute termination of tachycardia episodes. This Phase 3 open-label extension study is evaluating the long-term safety and effectiveness of etripamil in patients with recurrent episodes, while enabling continued access to treatment. The drug is acting by inhibiting calcium influx in cardiac cells, thereby slowing atrioventricular nodal conduction. The study is enrolling by invitation and is expected to be completed by April 2026, assessing real-world usability and sustained therapeutic benefit.

Drug: CRD-4730

CRD-4730 is an investigational, orally administered small-molecule therapy being developed by Cardurion Pharmaceuticals, Inc. for ventricular tachycardia associated with CPVT. The drug is targeting abnormal calcium handling in cardiac cells, aiming to stabilize heart rhythm and reduce arrhythmic episodes. This Phase 2 study is evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in a randomized, placebo-controlled, repeat-dose setting. The trial is enrolling patients and is expected to be completed by April 2027, while assessing dose-response and therapeutic potential.

Drug: SGT-501

SGT-501, developed by Solid Biosciences Inc. as an AAV-based gene therapy targeting catecholaminergic polymorphic ventricular tachycardia (CPVT). The Phase 1b study is evaluating the safety, tolerability, and optimal dose of a single intravenous administration in both adult and pediatric patients. The therapy is delivering a functional CASQ2 gene to cardiac cells, enhancing calcium buffering and stabilizing RYR2 channels to maintain normal heart rhythm. The trial is recruiting and is expected to reach primary completion by June 2027, with full study completion anticipated by May 2031.

Key Questions Answered in the Ventricular Tachycardia (V-tach or VT) Pipeline Insight Report

• Which companies/institutions are leading ventricular tachycardia (V-tach or VT) drug development?
• Which company is leading the ventricular tachycardia (V-tach or VT) pipeline development activities?
• What is the current ventricular tachycardia (V-tach or VT) commercial assessment?
• What are the opportunities and challenges present in the ventricular tachycardia (V-tach or VT) pipeline landscape?
• What is the efficacy and safety profile of ventricular tachycardia (V-tach or VT) pipeline drugs?
• Which company is conducting major trials for ventricular tachycardia (V-tach or VT) drugs?
• Which companies/institutions are involved in ventricular tachycardia (V-tach or VT) collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in ventricular tachycardia (V-tach or VT)?

Reasons To Buy This Report

The Ventricular Tachycardia (V-tach or VT) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for ventricular tachycardia (V-tach or VT). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ventricular tachycardia (V-tach or VT) collaborations, regulatory environments, and potential growth opportunities.